TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Carbon Nanotube Enabled Solid-State Head CT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Medically stable patient with head trauma or known intracranial hemorrhage (subdural or intraparenchymal) or skull fractures~* Patient has undergone conventional head CT imaging at UNC hospitals within the past 24 hours or will undergo a CT scan of the head~* Willing and able to provide written informed consent~Exclusion Criteria:~* Unable to provide consent~* Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine β-HCG results, obtained within 24 hours prior to the research scan, or on the basis of patient history, e.g., tubal ligation, hysterectomy or a minimum of 1 year without menses)~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Head Trauma or Brain Bleed (Type: EXPERIMENTAL): Medically stable patients who have undergone conventional head CT imaging undergo imaging within 24 hours using the s-HCT system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating Social Competence in Youth With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with high-functioning ASD (IQ \> or = to 70).~Exclusion Criteria:~* Children who evidence aggression toward other people.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- SENSE Theatre (Type: EXPERIMENTAL): SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
- Tackling Teenage Together (Type: ACTIVE_COMPARATOR): The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* (Type I, type II) diabetic patients age range (18-45) years, with diabetic peripheral neuropathy proved by clinical assessment and nerve conduction who did not receive treatment for diabetic peripheral neuropathy.~Exclusion Criteria:~* Decompensated cardiac, renal or liver disease. Associated autoimmune diseases Associated endocrinal diseases Pregnancy, usage of contraceptive pills or steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- mesenchymal stem cells (Type: EXPERIMENTAL): The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R\&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine and Outpatient Gynecologic Laparoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients undergoing outpatient laparoscopic gynecologic surgery~* American society of anesthesiologists class (ASA) Physical status (PS) I and II~* Age between 18 and 64 years~* Fluent in English~* Body mass index (BMI) less than 35~Exclusion Criteria:~* History of allergy to local anesthetics~* History of chronic opioid use~* Pregnant patients~* Body Mass Index (BMI) greater than 35~* History of electrocardiogram (EKG) abnormalities~* Hepatic Impairment~* History of congestive heart failure~* Electrocardiogram (EKG) abnormalities~* History of heart block (subject with history of heart block)~* Current use of anti-arrhythmic medications~Drop -Outs:~* Patient or surgeon request~* Conversion of the surgery from laparoscopic to open

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will receive the same volume of saline infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- 1 or 2 sites of biopsy-confirmed squamous cell or basal cell carcinomas limited to head and neck regions~Inclusion Criteria for Prospective Arm:~* Patients wishing to receive oral midazolam in a non-blinded fashion will not be excluded based on the size of an individual tumor, total number of tumors, or prior history of oral midazolam~* No upper weight limitation~Exclusion Criteria:~* Prior history of allergy to midazolam or any of the syrup components~* History of hypersensitivity to other benzodiazepines~* Congestive heart failure (AHA Class III and IV)~* Renal failure requiring hemodialysis~* End-stage liver failure~* Chronic alcoholism or alcohol intoxication within 24 hours of surgery~* Untreated or uncontrolled open angle glaucoma~* Uncontrolled hypertension~* History of psychoses or affective disorders~* Neuromuscular disorders such as myasthenia gravis~* Chronic obstructive pulmonary disease~* Patients on medications interfering with renal excretion or microsomal metabolism unless the last dose was taken greater than or equal to 5 half-lives prior to surgery~* Patients weighing less than 100 lb (45 kg)~* Pregnant women; women of childbearing potential will be required to take an in-office urine pregnancy test.~* Breast-feeding mothers must stop breast-feeding for 7 days after taking midazolam to take part in this study~Additional Exclusion Criteria for Randomized Arms:~* Patients with a single cancer \> 5 cm in the greatest dimension or with more than 2 cancers~* Patients who were previously premedicated with oral midazolam during prior Mohs micrographic surgery episodes~* Patients weighing more than 220 lb (100 kg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Randomized Midazolam (Type: ACTIVE_COMPARATOR): Single-dose midazolam
- Placebo (Type: PLACEBO_COMPARATOR): None
- Prospective Midazolam (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AGC or EGC confirmed by endoscopy~* Histologically confirmed adenocarcinoma of stomach~* Helicobacter pylori infection was confirmed by biopsy and CLO~* Pre op CT stage: IA, IB, II, IIIA according to UICC TNM classification system~* Pre op biopsy (body LC side) shows either intestinal metaplasia or glandular atrophy (at least grade 1)~* Tumor location is suitable for subtotal gastrectomy- i.e. at or distal to lower body~* Informed consent should be signed~Exclusion Criteria:~* Recurrent gastric cancer~* Previous serious side effect to antibiotics~* H. pylori eradication treatment history~* Other malignancy within the past 5 years~* Pregnant or nursing women~* Serious concurrent infection or nonmalignant disease such as liver cirrhosis, renal failure, cardiovascular diseases~* Psychiatric disorder that would preclude compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- H. pylori eradication (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pentax Airway Scope (AWS) Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject is at least 18 years old~* BMI between 30 and 50~* scheduled for elective surgery requiring orotracheal intubation~Exclusion Criteria:~* a known difficult airway~* loose teeth~* subject pregnancy~* rapid sequence induction required~* subject is unable to give consent~* anesthesiologist considered use of the Pentax AWS to be contraindicated~* special endotracheal tube (ETT) is needed for the case.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macintosh laryngoscope (Type: ACTIVE_COMPARATOR): Intubation with a Macintosh laryngoscope
- Pentax AWS (Type: ACTIVE_COMPARATOR): Intubation with a Pentax AWS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with mixed dyslipidemia~* Subjects agree to utilize adequate birth control methods and to adhere to the American Heart Association (AHA) diet.~Exclusion Criteria:~* Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.~* Patients who are taking certain medications or unstable dose of specific medications.~* Women who are pregnant or plan on becoming pregnant, or women who are lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): ABT-335 + 20 mg simvastatin
- B (Type: ACTIVE_COMPARATOR): ABT-335 + 40 mg simvastatin
- C (Type: PLACEBO_COMPARATOR): ABT-335 monotherapy
- D (Type: PLACEBO_COMPARATOR): 20 mg simvastatin monotherapy
- E (Type: PLACEBO_COMPARATOR): 40 mg simvastatin monotherapy
- F (Type: PLACEBO_COMPARATOR): 80 mg simvastatin monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gene Therapy for Blindness Caused by Choroideremia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study,~* Male aged 18 years or above,~* Diagnosed with choroideraemia and in good health,~* Active disease with SLO changes visible within the macula region,~* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study,~* Vision at least 6/60 or better in the study eye.~Exclusion Criteria:~* Female and child participants (under the age of 18),~* Men unwilling to use barrier contraception methods, if relevant,~* Previous history of retinal surgery or ocular inflammatory disease (uveitis),~* Grossly asymmetrical disease or other ocular morbidity which might confound use of the fellow eye as a long-term control,~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study,~* Participants who have participated in another research study involving an investigational product in the previous 12 weeks.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: EXPERIMENTAL): Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
- Dose 2 (Type: EXPERIMENTAL): Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing the Efficacy in Adults With Cold of HEalsea Rescue*

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male/Female subjects \>18 years~2. Acute infectious rhinitis/rhinosinusitis for ≤48h before trial entry~3. Symptoms of headache, muscle ache, chilliness, sore throat, blocked nose, runny nose, cough, sneezing with a score ≤9 (according to a self-rated symptom score; scale: 0 → 3 \[0: no symptom to 3: severe intensity\])~4. At least one of these symptoms: sore throat, runny nose or blocked nose (i.e., with a score ≥1)~5. Willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the information consent form~6. Patient with a smartphone and an internet connection.~Exclusion Criteria:~1. Known hypersensitivity/allergy to any component of the test device~2. Medical history or any current disease that is considered by the investigator as a reason for non-inclusion~3. Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps~4. History of nasal or sinus surgery that in the opinion of the investigator may influence symptom scores~5. Antibiotic intake within 2 weeks before screening~6. Systemic or local corticosteroids (nasal route or inhalation) within 4 weeks before screening~7. Antihistamines intake for allergy when treatment was started from less than 4 weeks~8. Chronic decongestant use~9. Recent (within the previous 2 days) intake of a common cold medicine that in the opinion of the investigator may influence symptom score at screening (NSAID, nasal decongestants, cough medicines)~10. Pregnant/Lactating female or absence of efficient contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Healsea Rescue* group (Type: EXPERIMENTAL): Subjects will receive Healsea Rescue\* according to its intended use.
- Placebo group (Type: PLACEBO_COMPARATOR): Subjects will receive Placebo according to identical posology, instructions for use, contraindication, precaution of use and labelling to those of Healsea Rescue.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patients with AML aged from 18 to 65 years~* Eastern Cooperative Oncology Group (ECOG) performance \< 2~* High risk group for relapse~  1. Complete remission (CR) 1 with unfavorable prognostic factor; presenting white blood cell \> 100,000/microliter or prior myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) or MDS/MPN or cytogenetics \& molecular features (intermediate and adverse)~ 2. CR2 or CR3 at transplantation~* No HLA-matched sibling and unrelated donor (HLA-A, -B, -C, and -DRB1)~* Acceptable organ function defined as serum creatinine \< 2 mg/dl, unless considered due to leukemia and serum bilirubin \< 3 mg/dl, unless considered due to leukemia~* Written informed consent form~Exclusion Criteria~* Active uncontrolled infections~* Corrected pulmonary diffusion capacity of \<40%~* Cardiac ejection fraction of \<35%~* ECOG performance status :2, 3, 4~* Active central nervous system involvement of disease~* Serological evidence of infection with HIV~* Pregnancy or breastfeeding~* Patient who are not suitable for the trial in accordance with principal investigator's decision

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplants from 8/8-matched unrelated (Type: ACTIVE_COMPARATOR): Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
- Transplants from family-mismatched/haploidentical donors (Type: EXPERIMENTAL): Participants will receive FMT using a reduced intensity conditioning regimens.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients 18 years old or older.~* Patients with a diagnosis of hypertension.~* Patients who are eligible and consent to participate in the study~Exclusion Criteria:~* Severe hypertension~* Previous or current diagnosis of heart failure.~* History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed NSCLC~* Age 18 -75 years~* Performance status (WHO) \<2~* Patients progressing after first-line docetaxel/gemcitabine treatment~* Adequate bone marrow (absolute neutrophil count \>1000/mm3, platelet count \>100000/mm3, hemoglobin \> 9 gr/ mm3)~* Adequate liver (bilirubin \<1.5 times upper limit of normal), renal (Creatinine clearance \> 50mg/min) and cardiac (LVEF \>50%) function~* Presence of measurable disease (according to RESIST criteria)~* Informed consent~Exclusion Criteria:~* Psychiatric illness or social situation that would preclude study compliance'~* Other concurrent uncontrolled illness.~* Other invasive malignancy within the past 5 years except nonmelanoma skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): IC
- 2 (Type: EXPERIMENTAL): PC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete